KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Income (2017 - 2025)

Amneal Pharmaceuticals has reported Operating Income over the past 9 years, most recently at $112.0 million for Q4 2025.

  • Quarterly results put Operating Income at $112.0 million for Q4 2025, up 47.81% from a year ago — trailing twelve months through Dec 2025 was $394.1 million (up 58.06% YoY), and the annual figure for FY2025 was $394.1 million, up 58.06%.
  • Operating Income for Q4 2025 was $112.0 million at Amneal Pharmaceuticals, up from $70.3 million in the prior quarter.
  • Over the last five years, Operating Income for AMRX hit a ceiling of $112.0 million in Q4 2025 and a floor of -$198.6 million in Q2 2022.
  • Median Operating Income over the past 5 years was $56.5 million (2021), compared with a mean of $45.3 million.
  • Biggest five-year swings in Operating Income: surged 1071.05% in 2021 and later plummeted 395.92% in 2022.
  • Amneal Pharmaceuticals' Operating Income stood at $11.2 million in 2021, then soared by 222.43% to $36.0 million in 2022, then crashed by 60.61% to $14.2 million in 2023, then surged by 434.02% to $75.8 million in 2024, then surged by 47.81% to $112.0 million in 2025.
  • The last three reported values for Operating Income were $112.0 million (Q4 2025), $70.3 million (Q3 2025), and $111.4 million (Q2 2025) per Business Quant data.